Tg Therapeutics (TGTX) Operating Leases (2019 - 2025)
Historic Operating Leases for Tg Therapeutics (TGTX) over the last 7 years, with Q3 2025 value amounting to $7.3 million.
- Tg Therapeutics' Operating Leases fell 1319.63% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 1319.63%. This contributed to the annual value of $8.1 million for FY2024, which is 1189.47% down from last year.
- Tg Therapeutics' Operating Leases amounted to $7.3 million in Q3 2025, which was down 1319.63% from $7.6 million recorded in Q2 2025.
- In the past 5 years, Tg Therapeutics' Operating Leases registered a high of $10.6 million during Q3 2022, and its lowest value of $7.3 million during Q3 2025.
- In the last 5 years, Tg Therapeutics' Operating Leases had a median value of $9.8 million in 2023 and averaged $9.3 million.
- Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 560.88% in 2022, then crashed by 1319.63% in 2025.
- Quarter analysis of 5 years shows Tg Therapeutics' Operating Leases stood at $9.8 million in 2021, then increased by 5.05% to $10.3 million in 2022, then decreased by 10.76% to $9.2 million in 2023, then dropped by 11.89% to $8.1 million in 2024, then fell by 10.14% to $7.3 million in 2025.
- Its Operating Leases stands at $7.3 million for Q3 2025, versus $7.6 million for Q2 2025 and $7.9 million for Q1 2025.